Omnicell Announces Second Quarter 2024 Results
Omnicell (NASDAQ:OMCL) announced strong Q2 2024 results, exceeding guidance across all metrics. Total revenues were $277 million, down 7% year-over-year. GAAP net income was $0.08 per diluted share, while non-GAAP net income reached $0.51 per diluted share. The company reported $557 million in cash and cash equivalents and $571 million in total debt. Omnicell raised its 2024 non-GAAP EBITDA and earnings per share guidance, projecting full-year revenues between $1.070 billion and $1.110 billion. The company's XT Amplify program is gaining market momentum, and strategic partnerships are enhancing pharmacy performance. Omnicell remains focused on innovation and streamlining operations to drive long-term growth and shareholder returns.
Omnicell (NASDAQ:OMCL) ha annunciato risultati solidi per il Q2 2024, superando le previsioni in tutti i parametri. I ricavi totali ammontano a 277 milioni di dollari, con una diminuzione del 7% rispetto all'anno precedente. L'utile netto GAAP è stato di 0,08 dollari per azione diluita, mentre l'utile netto non-GAAP ha raggiunto 0,51 dollari per azione diluita. L'azienda ha riportato 557 milioni di dollari in contante e equivalenti di contante e 571 milioni di dollari in debito totale. Omnicell ha aumentato le previsioni per l'EBITDA non-GAAP e l'utile per azione del 2024, prevedendo un fatturato annuo compreso tra 1,070 miliardi e 1,110 miliardi di dollari. Il programma XT Amplify dell'azienda sta guadagnando slancio sul mercato e le partnership strategiche stanno migliorando le performance delle farmacie. Omnicell rimane focalizzata sull'innovazione e sull'ottimizzazione delle operazioni per stimolare la crescita a lungo termine e i ritorni per gli azionisti.
Omnicell (NASDAQ:OMCL) anunció resultados sólidos para el Q2 2024, superando las expectativas en todos los indicadores. Los ingresos totales fueron de 277 millones de dólares, una disminución del 7% en comparación con el año anterior. El ingreso neto GAAP fue de 0.08 dólares por acción diluida, mientras que el ingreso neto no-GAAP alcanzó 0.51 dólares por acción diluida. La compañía reportó 557 millones de dólares en efectivo y equivalentes de efectivo y 571 millones de dólares en deuda total. Omnicell elevó su guía para el EBITDA no-GAAP y las ganancias por acción en 2024, proyectando ingresos anuales entre 1.070 y 1.110 millones de dólares. El programa XT Amplify de la compañía está ganando impulso en el mercado, y las alianzas estratégicas están mejorando el desempeño de las farmacias. Omnicell sigue centrada en la innovación y en optimizar operaciones para impulsar el crecimiento a largo plazo y los retornos para los accionistas.
Omnicell (NASDAQ:OMCL)은 2024년 2분기 강력한 실적을 발표하며 모든 지표에서 가이던스를 초과 달성했습니다. 총 수익은 2억 7,700만 달러로, 전년 대비 7% 감소했습니다. GAAP 기준 순이익은 희석주당 0.08달러였으며, 비GAAP 기준 순이익은 희석주당 0.51달러에 달했습니다. 회사는 5억 5,700만 달러의 현금 및 현금성 자산과 5억 7,100만 달러의 총 부채를 보고했습니다. Omnicell은 2024년 비GAAP EBITDA와 주당 순이익 가이던스를 상향 조정하며 전체 연간 수익을 10억 7,000만 달러에서 11억 1,000만 달러 사이로 예상하고 있습니다. 회사의 XT Amplify 프로그램은 시장에서 모멘텀을 얻고 있으며, 전략적 파트너십이 약국 성과를 향상시키고 있습니다. Omnicell은 혁신과 운영 효율성 향상에 집중하여 장기적인 성장과 주주 수익을 추진하고 있습니다.
Omnicell (NASDAQ:OMCL) a annoncé des résultats solides pour le T2 2024, dépassant les prévisions sur tous les indicateurs. Les revenus totaux s'élevaient à 277 millions de dollars, en baisse de 7 % par rapport à l'année précédente. Le bénéfice net GAAP était de 0,08 dollar par action diluée, tandis que le bénéfice net non-GAAP a atteint 0,51 dollar par action diluée. L'entreprise a rapporté 557 millions de dollars en liquidités et équivalents de liquidités et 571 millions de dollars en dettes totales. Omnicell a relevé ses prévisions d'EBITDA non-GAAP et de bénéfice par action pour 2024, projetant des revenus annuels compris entre 1,070 milliard et 1,110 milliard de dollars. Le programme XT Amplify de l'entreprise prend de l'ampleur sur le marché, et les partenariats stratégiques améliorent la performance des pharmacies. Omnicell reste concentrée sur l'innovation et l'optimisation des opérations pour stimuler la croissance à long terme et le retour sur investissement pour les actionnaires.
Omnicell (NASDAQ:OMCL) gab bekannt, dass die Ergebnisse für das 2. Quartal 2024 stark waren und alle Ziele übertroffen wurden. Die Gesamterlöse betrugen 277 Millionen Dollar, ein Rückgang von 7 % im Vergleich zum Vorjahr. Der GAAP-Nettogewinn belief sich auf 0,08 Dollar pro verwässerter Aktie, während der Non-GAAP-Nettogewinn 0,51 Dollar pro verwässerter Aktie erreichte. Das Unternehmen meldete 557 Millionen Dollar an liquiden Mitteln und Zahlungsmitteläquivalenten sowie 571 Millionen Dollar an Gesamtschulden. Omnicell erhöhte seine Prognosen für das Non-GAAP-EBITDA und den Gewinn pro Aktie für 2024 und erwartet jahresweite Einnahmen zwischen 1,070 Milliarden und 1,110 Milliarden Dollar. Das XT Amplify-Programm des Unternehmens gewinnt Marktanteile, und strategische Partnerschaften verbessern die Leistung der Apotheken. Omnicell konzentriert sich weiterhin auf Innovation und die Optimierung der Abläufe, um das langfristige Wachstum und die Rendite für die Aktionäre voranzutreiben.
- Q2 2024 results exceeded guidance across all key metrics
- Non-GAAP net income of $0.51 per diluted share
- Strong cash position with $557 million in cash and cash equivalents
- Raised 2024 non-GAAP EBITDA and earnings per share guidance
- XT Amplify program gaining market momentum
- Strategic partnerships enhancing pharmacy performance
- Total revenues decreased 7% year-over-year to $277 million
- Total debt of $571 million
- Challenging environment for some health system customers
- Impact of XT Series automated dispensing systems lifecycle replacement cycle
Insights
Omnicell's Q2 2024 results paint a mixed picture. While the company exceeded its guidance across all metrics, there are some concerning trends to note. Total revenues of
On the positive side, GAAP net income per diluted share remained stable at
The updated guidance for 2024 is particularly noteworthy. Omnicell has raised its non-GAAP EBITDA and EPS forecasts, indicating confidence in its ability to improve profitability despite revenue pressures. The full-year revenue guidance of
Investors should closely monitor the success of initiatives like XT Amplify and the company's efforts to streamline operations and optimize costs. These could be key drivers for future performance and stock valuation.
Omnicell's Q2 results reflect the broader trends in healthcare technology adoption. The
The XT Amplify program, including solutions like XTExtend, demonstrates Omnicell's commitment to continuous innovation. This approach could help extend the lifecycle of existing installations and potentially smooth out revenue fluctuations in the future. The emphasis on enhancing security and user experience aligns well with healthcare providers' priorities.
The partnership between EnlivenHealth and independent pharmacies for the Scope of Practice and Reimbursement Snapshot is a smart move. It positions Omnicell to capitalize on the expanding role of pharmacies in healthcare delivery, potentially opening up new revenue streams.
The adoption of Omnicell's Central Pharmacy Dispensing Services by Baptist Health for its multi-state operations is a significant win. It validates the company's value proposition in addressing staffing challenges and improving efficiency in pharmacy operations. This could serve as a reference case for other large health systems considering similar investments.
Looking ahead, Omnicell's focus on connected devices and recurring revenue services aligns well with industry trends towards data-driven, automated healthcare delivery. The success of this strategy will be important for the company's long-term growth prospects.
Results exceed previously issued second quarter guidance across all metrics
Total revenues of
GAAP net income per diluted share of
Non-GAAP net income per diluted share of
Raises 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance
Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell, said, “We are pleased with the second quarter results that we announced today, which exceeded our previously issued guidance across all key metrics, including revenue, non-GAAP EBITDA and non-GAAP earnings per share. The strong results this quarter reflect improving macro trends and solid execution by the Omnicell team.”
“We have concluded a holistic review of our business and have identified several potential areas across our operations where we believe we can drive synergies, streamline processes, and optimize our cost structure. We are investing in innovation to support our XT fleet and other areas of pharmacy automation, and it appears to be resonating well with our customers. The holistic business review validates our confidence in our refreshed strategy with an emphasis on connected devices, while also continuing to offer services that are expected to increase our recurring revenue. We are excited about our multiyear journey focused on bringing outcomes-centric solutions to the market. We remain confident in Omnicell’s long-term opportunities and intend to remain focused on strong execution and enhancing stockholders returns,” Mr. Lipps concluded.
Financial Results
Total revenues for the second quarter of 2024 were
Total GAAP net income for the second quarter of 2024 was
Total non-GAAP net income for the second quarter of 2024 was
Total non-GAAP EBITDA for the second quarter of 2024 was
Balance Sheet
As of June 30, 2024, Omnicell’s balance sheet reflected cash and cash equivalents of
As of June 30, 2024, the Company had
Corporate Highlights
-
Omnicell Central Pharmacy Dispensing Services are a cornerstone of
Kentucky -based Baptist Health’s new Central Pharmacy Services Center, a 102,000-square-foot facility that will support medication management for its nine hospitals acrossKentucky and surrounding states. Baptist Health selected Omnicell’s robotics and services in an effort to alleviate staffing challenges while focusing on improving quality, patient safety, and efficiency, which should allow them to advance closer to the industry-defined vision of the Autonomous Pharmacy.
- XT Amplify is gaining market momentum as health systems are provided the opportunity to maximize value for their XT Series automated dispensing system technology through solutions like XTExtend, a comprehensive console swap that is intended to provide a high level of security while enhancing the nurse user experience. XT Amplify, launched earlier this year, is a multi-year innovation program focused on continuous innovation intended to drive enhanced clinical and operational outcomes at the points of care and within pharmacies.
-
Later today EnlivenHealth® will be issuing a press release announcing a strategic partnership for a new Scope of Practice and Reimbursement Snapshot, a first-of-its-kind solution that will give the strategic partner’s independent pharmacy members access to up-to-date information regarding clinical services they can provide in their state and reimbursement details for those services. We believe that providing this new service emphasizes EnlivenHealth’s commitment to elevating pharmacies to the forefront of healthcare by contributing to clinical service expansion and providing greater access to patient care through local independent pharmacies across the
U.S.
- Omnicell Specialty Pharmacy Services continues to enhance pharmacy performance and clinical outcomes for our customers. At the recent Healthcare Financial Management Association conference, the Administrative Director of Pharmacy and Supply Chain for Blessing Health System shared how an optimized approach to Specialty Pharmacy supports best-in-class patient care while driving growth.
- Omnicell announced continued support for the global charity Mercy Ships with the donation of solutions from the recently announced XT Amplify program. Mercy Ships travels to developing nations to provide sorely needed, quality healthcare for underserved patients. With the recent donation of XTExtend, Omnicell will provide a comprehensive console swap for previously implemented XT Series automated dispensing systems to enhance security and improve the user experience.
2024 Guidance
Based on strong first half performance and current visibility of the business, the Company is updating the previously provided 2024 annual guidance metrics. For the full year 2024, the Company expects bookings to be between
For the third quarter of 2024, the Company expects total revenues to be between
The table below summarizes Omnicell’s third quarter and full year 2024 guidance outlined above.
|
Q3 2024 |
|
2024 |
Bookings |
Not provided |
|
|
Total Revenues |
|
|
|
Product Revenues |
|
|
|
Service Revenues |
|
|
|
Technical Services Revenues |
Not provided |
|
|
Advanced Services Revenues |
Not provided |
|
|
Non-GAAP EBITDA |
|
|
|
Non-GAAP Earnings Per Share |
|
|
|
The Company does not provide guidance for GAAP net income or GAAP earnings per share, nor a reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures on a forward-looking basis, because it is unable to predict certain items contained in the GAAP measures without unreasonable efforts. These forward-looking non-GAAP financial measures do not include certain items, which may be significant, including, but not limited to, unusual gains and losses, costs associated with future restructurings, acquisition-related expenses, and certain tax and litigation outcomes.
Omnicell Conference Call Information
Omnicell will hold a conference call today, Thursday, August 1, 2024 at 8:30 a.m. ET to discuss second quarter 2024 financial results. The conference call can be monitored by dialing (800) 715-9871 in the
About Omnicell
Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics, smart devices, intelligent software, and expert services, Omnicell solutions are helping healthcare facilities worldwide to reduce costs, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.
From time to time, Omnicell may use the Company’s investor relations website and other online social media channels, including its LinkedIn page www.linkedin.com/company/omnicell and Facebook page www.facebook.com/omnicellinc, to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure (“Reg FD”).
OMNICELL, the Omnicell logo, and ENLIVENHEALTH are registered trademarks of Omnicell, Inc. or one of its subsidiaries.
Forward-Looking Statements
To the extent any statements contained in this press release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control. Such statements include, but are not limited to, Omnicell’s projected bookings, revenues, including product, service, technical services and Advanced Services revenues, non-GAAP EBITDA, and non-GAAP earnings per share; expectations regarding our products and services and developing new or enhancing existing products and solutions and the related objectives and expected benefits (and any implied financial impact); results of our holistic review; our ability to improve long-term value; and statements about Omnicell’s strategy, plans, objectives, promise and purpose, goals, including innovation, environment, social and governance goals and strategies, opportunities, market or Company outlook, expense management, and planned investments. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (ii) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (iv) delays in installations of our medication management solutions or our more complex medication packaging systems, (v) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, and its ability to acquire companies, businesses, or technologies and successfully integrate such acquisitions, (vi) ability to realize the benefits of our expense containment initiatives, (vii) risks related to failing to maintain expected service levels when providing our Advanced Services or retaining our Advanced Services customers, (viii) Omnicell’s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (ix) risks related to climate change, legal, regulatory or market measures to address climate change and related emphasis on ESG matters by various stakeholders, (x) changes to the 340B Program, (xi) Omnicell’s substantial debt, which could impair its financial flexibility and access to capital, (xii) covenants in our credit agreement could restrict our business and operations, (xiii) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (xiv) risks presented by government regulations, legislative changes, fraud and anti-kickback statues, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, including any potential governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity as a result of the previously disclosed ransomware incident, (xv) any disruption in Omnicell’s information technology systems and breaches of data security or cyber-attacks on its systems or solutions, including the previously disclosed ransomware incident and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (xvi) risks associated with operating in foreign countries, (xvii) Omnicell’s ability to recruit and retain skilled and motivated personnel, (xviii) Omnicell’s ability to protect its intellectual property, (xix) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (xx) Omnicell’s dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, (xxi) fluctuations in quarterly and annual operating results may make our future operating results difficult to predict, (xxii) failing to meet (or significantly exceeding) our publicly announced financial guidance, and (xxiii) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.
Use of Non-GAAP Financial Information
This press release contains financial measures that are not calculated in accordance with
Our non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP EBITDA, and non-GAAP EBITDA margin are exclusive of certain items to facilitate management’s review of the comparability of Omnicell’s core operating results on a period-to-period basis because such items are not related to Omnicell’s ongoing core operating results as viewed by management. We define our “core operating results” as those revenues recorded in a particular period and the expenses incurred within such period that directly drive operating income in such period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we believe we should invest in research and development, fund infrastructure growth, and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results: non-GAAP gross profit and non-GAAP gross margin exclude from their GAAP equivalents items a), b), e), and g) below; non-GAAP operating expenses excludes from its GAAP equivalents items a), b), c), d), e), g and h) below; non-GAAP income from operations and non-GAAP operating margin exclude from their GAAP equivalents items a), b), c), d), e), g and h) below; and non-GAAP net income and non-GAAP net income per diluted share exclude from their GAAP equivalents items a) through h) below. Non-GAAP EBITDA is defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. Non-GAAP EBITDA and non-GAAP EBITDA margin exclude from their GAAP equivalents items a), c), d), e), f), g and h) below:
a) |
|
Share-based compensation expense. We excluded from our non-GAAP results the expense related to equity-based compensation plans as it represents expenses that do not require cash settlement from Omnicell. |
b) |
|
Amortization of acquired intangible assets. We excluded from our non-GAAP results the intangible assets amortization expense resulting from our past acquisitions. These non-cash charges are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results. |
c) |
|
Acquisition-related expenses. We excluded from our non-GAAP results the expenses related to recent acquisitions, including amortization of representations and warranties insurance. These expenses are unrelated to our ongoing operations, vary in size and frequency, and are subject to significant fluctuations from period to period due to varying levels of acquisition activity. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. |
d) |
|
Impairment and abandonment of operating lease right-of-use and other assets related to facilities. We excluded from our non-GAAP results the impairment and abandonment of certain operating lease right-of-use assets, as well as property and equipment, incurred in connection with restructuring activities for optimization of certain leased facilities. These non-cash charges are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results. |
e) |
|
Severance-related expenses. We excluded from our non-GAAP results the expenses related to restructuring events. These expenses are unrelated to our ongoing operations, vary in size and frequency, and are subject to significant fluctuations from period to period due to varying levels of restructuring activity. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. |
f) |
|
Amortization of debt issuance costs. Debt issuance costs represent costs associated with the issuance of revolving credit facilities and convertible senior notes. The costs include underwriting fees, original issue discount, ticking fees, and legal fees. These non-cash expenses are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results. |
g) |
|
RDS restructuring. We excluded from our non-GAAP results the nonrecurring restructuring charges related to the wind down of the Company’s Medimat Robotic Dispensing System (“RDS”) product line. For the period ended June 30, 2024, those charges consisted primarily of inventory write-down, severance and other related expenses. These expenses are unrelated to our ongoing operations and we believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. |
h) |
|
Executives transition costs. We excluded from our non-GAAP results the executives transition costs associated with the departure of certain executive officers, primarily consisting of severance expenses. These expenses are unrelated to our ongoing operations and we do not expect them to occur in the ordinary course of business. We believe that excluding these expenses provides more meaningful comparisons of the financial results to our historical operations and forward-looking guidance, and to the financial results of peer companies. |
Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell’s control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational or non-cash expenses involving stock compensation plans or other items.
We believe that the presentation of non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP EBITDA, and non-GAAP EBITDA margin is warranted for several reasons:
a) |
|
Such non-GAAP financial measures provide an additional analytical tool for understanding Omnicell’s financial performance by excluding the impact of items which may obscure trends in the core operating results of the business. |
b) |
|
Since we have historically reported non-GAAP results to the investment community, we believe the inclusion of non-GAAP numbers provides consistency and enhances investors’ ability to compare our performance across financial reporting periods. |
c) |
|
These non-GAAP financial measures are employed by management in its own evaluation of performance and are utilized in financial and operational decision-making processes, such as budget planning and forecasting. |
d) |
|
These non-GAAP financial measures facilitate comparisons to the operating results of other companies in our industry, which also use non-GAAP financial measures to supplement their GAAP results (although these companies may calculate non-GAAP financial measures differently than Omnicell does), thus enhancing the perspective of investors who wish to utilize such comparisons in their analysis of our performance. |
Set forth below are additional reasons why share-based compensation expense is excluded from our non-GAAP financial measures:
i) |
|
While share-based compensation calculated in accordance with Accounting Standards Codification (“ASC”) 718 constitutes an ongoing and recurring expense of Omnicell, it is not an expense that requires cash settlement by Omnicell. We therefore exclude these charges for purposes of evaluating core operating results. Thus, our non-GAAP measurements are presented exclusive of share-based compensation expense to assist management and investors in evaluating our core operating results. |
ii) |
|
We present ASC 718 share-based payment compensation expense in our reconciliation of non-GAAP financial measures on a pre-tax basis because the exact tax differences related to the timing and deductibility of share-based compensation under ASC 718 are dependent upon the trading price of Omnicell’s common stock and the timing and exercise by employees of their stock options. As a result of these timing and market uncertainties, the tax effect related to share-based compensation expense would be inconsistent in amount and frequency and is therefore excluded from our non-GAAP results. |
Non-GAAP diluted shares is defined as our GAAP diluted shares, excluding the impact of dilutive convertible senior notes for which the Company is economically hedged through its anti-dilutive convertible note hedge transaction. We believe non-GAAP diluted shares is a useful non-GAAP metric because it provides insight into the offsetting economic effect of the hedge transaction against potential conversion of the convertible senior notes.
Non-GAAP free cash flow is defined as net cash provided by operating activities less cash used for software development for external use and purchases of property and equipment. We believe free cash flow is important to enable investors to better understand and evaluate our ongoing operating results and allows for greater transparency in the review and understanding of our overall financial, operational, and economic performance, because free cash flow takes into account certain capital expenditures and cash used for software development necessary to operate our business.
As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell’s GAAP results. In the future, we expect to incur expenses similar to certain of the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are:
a) |
|
Omnicell’s equity incentive plans and stock purchase plans are important components of incentive compensation arrangements and will be reflected as expenses in Omnicell’s GAAP results for the foreseeable future under ASC 718. |
b) |
|
Other companies, including companies in Omnicell’s industry, may calculate non-GAAP financial measures differently than Omnicell, limiting their usefulness as a comparative measure. |
c) |
|
A limitation of the utility of free cash flow as a measure of financial performance is that it does not represent the total increase or decrease in Omnicell’s cash balance for the period. |
A detailed reconciliation between Omnicell’s non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release as well as in Omnicell’s other reports filed with or furnished to the SEC.
Omnicell, Inc. |
|||||||||||||||
Condensed Consolidated Statements of Operations |
|||||||||||||||
(Unaudited, in thousands, except per share data) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
|
|
|
|
|
|
|
|
||||||||
Revenues: |
|
|
|
|
|
|
|
||||||||
Product revenues |
$ |
156,580 |
|
$ |
188,436 |
|
$ |
289,875 |
|
|
$ |
374,151 |
|
||
Service revenues |
|
120,208 |
|
|
|
110,537 |
|
|
|
233,064 |
|
|
|
215,451 |
|
Total revenues |
|
276,788 |
|
|
|
298,973 |
|
|
|
522,939 |
|
|
|
589,602 |
|
Cost of revenues: |
|
|
|
|
|
|
|
||||||||
Cost of product revenues |
|
99,381 |
|
|
|
107,962 |
|
|
|
191,822 |
|
|
|
217,489 |
|
Cost of service revenues |
|
63,056 |
|
|
|
56,568 |
|
|
|
124,143 |
|
|
|
112,641 |
|
Total cost of revenues |
|
162,437 |
|
|
|
164,530 |
|
|
|
315,965 |
|
|
|
330,130 |
|
Gross profit |
|
114,351 |
|
|
|
134,443 |
|
|
|
206,974 |
|
|
|
259,472 |
|
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Research and development |
|
21,102 |
|
|
|
23,137 |
|
|
|
43,158 |
|
|
|
46,015 |
|
Selling, general, and administrative |
|
90,025 |
|
|
|
103,558 |
|
|
|
182,439 |
|
|
|
228,672 |
|
Total operating expenses |
|
111,127 |
|
|
|
126,695 |
|
|
|
225,597 |
|
|
|
274,687 |
|
Income (loss) from operations |
|
3,224 |
|
|
|
7,748 |
|
|
|
(18,623 |
) |
|
|
(15,215 |
) |
Interest and other income (expense), net |
|
4,973 |
|
|
|
4,461 |
|
|
|
8,989 |
|
|
|
6,242 |
|
Income (loss) before income taxes |
|
8,197 |
|
|
|
12,209 |
|
|
|
(9,634 |
) |
|
|
(8,973 |
) |
Provision for income taxes |
|
4,462 |
|
|
|
8,758 |
|
|
|
2,307 |
|
|
|
2,576 |
|
Net income (loss) |
$ |
3,735 |
|
|
$ |
3,451 |
|
|
$ |
(11,941 |
) |
|
$ |
(11,549 |
) |
Net income (loss) per share: |
|
|
|
|
|
|
|
||||||||
Basic |
$ |
0.08 |
|
|
$ |
0.08 |
|
|
$ |
(0.26 |
) |
|
$ |
(0.26 |
) |
Diluted |
$ |
0.08 |
|
|
$ |
0.08 |
|
|
$ |
(0.26 |
) |
|
$ |
(0.26 |
) |
Weighted-average shares outstanding: |
|
|
|
|
|
|
|
||||||||
Basic |
|
45,953 |
|
|
|
45,125 |
|
|
|
45,842 |
|
|
|
45,007 |
|
Diluted |
|
46,036 |
|
|
|
45,472 |
|
|
|
45,842 |
|
|
|
45,007 |
|
Omnicell, Inc. |
|||||||
Condensed Consolidated Balance Sheets |
|||||||
(Unaudited, in thousands) |
|||||||
|
June 30,
|
|
December 31,
|
||||
|
|
|
|
||||
ASSETS |
|||||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
556,781 |
|
$ |
467,972 |
||
Accounts receivable and unbilled receivables, net |
|
241,127 |
|
|
|
252,025 |
|
Inventories |
|
93,262 |
|
|
|
110,099 |
|
Prepaid expenses |
|
22,216 |
|
|
|
25,966 |
|
Other current assets |
|
82,282 |
|
|
|
71,509 |
|
Total current assets |
|
995,668 |
|
|
|
927,571 |
|
Property and equipment, net |
|
110,982 |
|
|
|
108,601 |
|
Long-term investment in sales-type leases, net |
|
50,302 |
|
|
|
42,954 |
|
Operating lease right-of-use assets |
|
26,438 |
|
|
|
24,988 |
|
Goodwill |
|
735,351 |
|
|
|
735,810 |
|
Intangible assets, net |
|
199,425 |
|
|
|
211,173 |
|
Long-term deferred tax assets |
|
40,555 |
|
|
|
32,901 |
|
Prepaid commissions |
|
49,882 |
|
|
|
52,414 |
|
Other long-term assets |
|
83,054 |
|
|
|
90,466 |
|
Total assets |
$ |
2,291,657 |
|
|
$ |
2,226,878 |
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|||||||
Current liabilities: |
|
|
|
||||
Accounts payable |
$ |
49,747 |
|
|
$ |
45,028 |
|
Accrued compensation |
|
48,940 |
|
|
|
51,754 |
|
Accrued liabilities |
|
158,119 |
|
|
|
149,276 |
|
Deferred revenues |
|
150,316 |
|
|
|
121,734 |
|
Total current liabilities |
|
407,122 |
|
|
|
367,792 |
|
Long-term deferred revenues |
|
67,931 |
|
|
|
58,622 |
|
Long-term deferred tax liabilities |
|
1,326 |
|
|
|
1,620 |
|
Long-term operating lease liabilities |
|
33,739 |
|
|
|
33,910 |
|
Other long-term liabilities |
|
7,514 |
|
|
|
6,318 |
|
Convertible senior notes, net |
|
571,217 |
|
|
|
569,662 |
|
Total liabilities |
|
1,088,849 |
|
|
|
1,037,924 |
|
Total stockholders’ equity |
|
1,202,808 |
|
|
|
1,188,954 |
|
Total liabilities and stockholders’ equity |
$ |
2,291,657 |
|
|
$ |
2,226,878 |
|
Omnicell, Inc. |
|||||||
Condensed Consolidated Statements of Cash Flows |
|||||||
(Unaudited, in thousands) |
|||||||
|
Six Months Ended June 30, |
||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
|
|
||||
Operating Activities |
|
|
|
||||
Net loss |
$ |
(11,941 |
) |
|
$ |
(11,549 |
) |
Adjustments to reconcile net loss to net cash provided by operating activities: |
|||||||
Depreciation and amortization |
|
42,090 |
|
|
|
44,054 |
|
Loss on disposal of assets |
|
221 |
|
|
|
993 |
|
Share-based compensation expense |
|
18,672 |
|
|
|
28,131 |
|
Deferred income taxes |
|
(7,948 |
) |
|
|
(11,019 |
) |
Amortization of operating lease right-of-use assets |
|
3,900 |
|
|
|
4,225 |
|
Impairment and abandonment of operating lease right-of-use assets related to facilities |
|
— |
|
|
|
7,815 |
|
Inventory write-down |
|
5,393 |
|
|
|
— |
|
Amortization of debt issuance costs |
|
1,943 |
|
|
|
2,091 |
|
Changes in operating assets and liabilities: |
|
|
|
||||
Accounts receivable and unbilled receivables |
|
10,898 |
|
|
|
26,463 |
|
Inventories |
|
11,160 |
|
|
|
17,820 |
|
Prepaid expenses |
|
3,750 |
|
|
|
3,576 |
|
Other current assets |
|
5,868 |
|
|
|
773 |
|
Investment in sales-type leases |
|
(8,056 |
) |
|
|
(1,707 |
) |
Prepaid commissions |
|
2,532 |
|
|
|
4,706 |
|
Other long-term assets |
|
1,218 |
|
|
|
43 |
|
Accounts payable |
|
4,751 |
|
|
|
(15,806 |
) |
Accrued compensation |
|
(2,814 |
) |
|
|
(20,980 |
) |
Accrued liabilities |
|
9,247 |
|
|
|
(4,646 |
) |
Deferred revenues |
|
22,085 |
|
|
|
16,540 |
|
Operating lease liabilities |
|
(5,512 |
) |
|
|
(5,396 |
) |
Other long-term liabilities |
|
1,196 |
|
|
|
(454 |
) |
Net cash provided by operating activities |
|
108,653 |
|
|
|
85,673 |
|
Investing Activities |
|
|
|
||||
External-use software development costs |
|
(7,381 |
) |
|
|
(6,685 |
) |
Purchases of property and equipment |
|
(18,508 |
) |
|
|
(21,772 |
) |
Net cash used in investing activities |
|
(25,889 |
) |
|
|
(28,457 |
) |
Financing Activities |
|
|
|
||||
Proceeds from issuances under stock-based compensation plans |
|
8,141 |
|
|
|
15,203 |
|
Employees’ taxes paid related to restricted stock units |
|
(1,291 |
) |
|
|
(3,465 |
) |
Change in customer funds, net |
|
(11,552 |
) |
|
|
(4,273 |
) |
Net cash provided by (used in) financing activities |
|
(4,702 |
) |
|
|
7,465 |
|
Effect of exchange rate changes on cash and cash equivalents |
|
(802 |
) |
|
|
148 |
|
Net increase in cash, cash equivalents, and restricted cash |
|
77,260 |
|
|
|
64,829 |
|
Cash, cash equivalents, and restricted cash at beginning of period |
|
500,979 |
|
|
|
352,835 |
|
Cash, cash equivalents, and restricted cash at end of period |
$ |
578,239 |
|
|
$ |
417,664 |
|
Reconciliation of cash, cash equivalents, and restricted cash to the Condensed Consolidated Balance Sheets: |
|||||||
Cash and cash equivalents |
$ |
556,781 |
|
|
$ |
399,464 |
|
Restricted cash included in other current assets |
|
21,458 |
|
|
|
18,200 |
|
Cash, cash equivalents, and restricted cash at end of period |
$ |
578,239 |
|
|
$ |
417,664 |
|
Omnicell, Inc. |
|||||||||||||||
Reconciliation of GAAP to Non-GAAP |
|||||||||||||||
(Unaudited, in thousands, except per share data and percentage) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
|
|
|
|
|
|
|
|
||||||||
Reconciliation of GAAP gross profit to non-GAAP gross profit: |
|
|
|
|
|
||||||||||
GAAP gross profit |
$ |
114,351 |
|
|
$ |
134,443 |
|
|
$ |
206,974 |
|
|
$ |
259,472 |
|
GAAP gross margin |
|
|
|
|
|
|
|
||||||||
Share-based compensation expense |
|
1,620 |
|
|
|
2,268 |
|
|
|
3,175 |
|
|
|
4,276 |
|
Amortization of acquired intangibles |
|
970 |
|
|
|
2,900 |
|
|
|
2,090 |
|
|
|
5,925 |
|
RDS restructuring |
|
5,348 |
|
|
|
— |
|
|
|
8,044 |
|
|
|
— |
|
Severance-related expenses |
|
— |
|
|
|
238 |
|
|
|
— |
|
|
|
382 |
|
Non-GAAP gross profit |
$ |
122,289 |
|
|
$ |
139,849 |
|
|
$ |
220,283 |
|
|
$ |
270,055 |
|
Non-GAAP gross margin |
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
||||||||
Reconciliation of GAAP operating expenses to non-GAAP operating expenses: |
|
|
|
|
|||||||||||
GAAP operating expenses |
$ |
111,127 |
|
|
$ |
126,695 |
|
|
$ |
225,597 |
|
|
$ |
274,687 |
|
GAAP operating expenses % to total revenues |
|
|
|
|
|
|
|
||||||||
Share-based compensation expense |
|
(8,411 |
) |
|
|
(11,821 |
) |
|
|
(15,497 |
) |
|
|
(23,855 |
) |
Amortization of acquired intangibles |
|
(4,702 |
) |
|
|
(5,135 |
) |
|
|
(9,542 |
) |
|
|
(10,352 |
) |
Acquisition-related expenses |
|
(246 |
) |
|
|
(246 |
) |
|
|
(492 |
) |
|
|
(492 |
) |
Impairment and abandonment of operating lease right-of-use and other assets related to facilities |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(8,420 |
) |
RDS restructuring |
|
(291 |
) |
|
|
— |
|
|
|
(867 |
) |
|
|
— |
|
Executives transition costs |
|
— |
|
|
|
(841 |
) |
|
|
— |
|
|
|
(841 |
) |
Severance-related expenses |
|
— |
|
|
|
(483 |
) |
|
|
— |
|
|
|
(5,653 |
) |
Non-GAAP operating expenses |
$ |
97,477 |
|
|
$ |
108,169 |
|
|
$ |
199,199 |
|
|
$ |
225,074 |
|
Non-GAAP operating expenses as a % of total revenues |
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
||||||||
Reconciliation of GAAP income (loss) from operations to non-GAAP income from operations: |
|||||||||||||||
GAAP income (loss) from operations |
$ |
3,224 |
|
|
$ |
7,748 |
|
|
$ |
(18,623 |
) |
|
$ |
(15,215 |
) |
GAAP operating loss % to total revenues |
|
|
|
|
(3.6)% |
|
(2.6)% |
||||||||
Share-based compensation expense |
|
10,031 |
|
|
|
14,089 |
|
|
|
18,672 |
|
|
|
28,131 |
|
Amortization of acquired intangibles |
|
5,672 |
|
|
|
8,035 |
|
|
|
11,632 |
|
|
|
16,277 |
|
Acquisition-related expenses |
|
246 |
|
|
|
246 |
|
|
|
492 |
|
|
|
492 |
|
Impairment and abandonment of operating lease right-of-use and other assets related to facilities |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
8,420 |
|
RDS restructuring |
|
5,639 |
|
|
|
— |
|
|
|
8,911 |
|
|
|
— |
|
Executives transition costs |
|
— |
|
|
|
841 |
|
|
|
— |
|
|
|
841 |
|
Severance-related expenses |
|
— |
|
|
|
721 |
|
|
|
— |
|
|
|
6,035 |
|
Non-GAAP income from operations |
$ |
24,812 |
|
|
$ |
31,680 |
|
|
$ |
21,084 |
|
|
$ |
44,981 |
|
Non-GAAP operating margin (non-GAAP operating income as a % of total revenues) |
|
|
|
|
|
|
|
||||||||
Omnicell, Inc. |
|||||||||||||||
Reconciliation of GAAP to Non-GAAP |
|||||||||||||||
(Unaudited, in thousands, except per share data and percentage) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
|
|
|
|
|
|
|
|
||||||||
Reconciliation of GAAP net income (loss) to non-GAAP net income: |
|||||||||||||||
GAAP net income (loss) |
$ |
3,735 |
|
|
$ |
3,451 |
|
|
$ |
(11,941 |
) |
|
$ |
(11,549 |
) |
Share-based compensation expense |
|
10,031 |
|
|
|
14,089 |
|
|
|
18,672 |
|
|
|
28,131 |
|
Amortization of acquired intangibles |
|
5,672 |
|
|
|
8,035 |
|
|
|
11,632 |
|
|
|
16,277 |
|
Acquisition-related expenses |
|
246 |
|
|
|
246 |
|
|
|
492 |
|
|
|
492 |
|
Impairment and abandonment of operating lease right-of-use and other assets related to facilities |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
8,420 |
|
RDS restructuring |
|
5,639 |
|
|
|
— |
|
|
|
8,911 |
|
|
|
— |
|
Executives transition costs |
|
— |
|
|
|
841 |
|
|
|
— |
|
|
|
841 |
|
Severance-related expenses |
|
— |
|
|
|
721 |
|
|
|
— |
|
|
|
6,035 |
|
Amortization of debt issuance costs |
|
972 |
|
|
|
1,046 |
|
|
|
1,943 |
|
|
|
2,091 |
|
Tax effect of the adjustments above (a) |
|
(2,631 |
) |
|
|
(2,287 |
) |
|
|
(4,825 |
) |
|
|
(7,173 |
) |
Non-GAAP net income |
$ |
23,664 |
|
|
$ |
26,142 |
|
|
$ |
24,884 |
|
|
$ |
43,565 |
|
|
|
|
|
|
|
|
|
||||||||
Reconciliation of GAAP net income (loss) per share - diluted to non-GAAP net income per share - diluted: |
|||||||||||||||
Shares - diluted GAAP |
|
46,036 |
|
|
|
45,472 |
|
|
|
45,842 |
|
|
|
45,007 |
|
Shares - diluted non-GAAP |
|
46,036 |
|
|
|
45,472 |
|
|
|
45,905 |
|
|
|
45,306 |
|
|
|
|
|
|
|
|
|
||||||||
GAAP net income (loss) per share - diluted |
$ |
0.08 |
|
|
$ |
0.08 |
|
|
$ |
(0.26 |
) |
|
$ |
(0.26 |
) |
Share-based compensation expense |
|
0.22 |
|
|
|
0.31 |
|
|
|
0.42 |
|
|
|
0.62 |
|
Amortization of acquired intangibles |
|
0.12 |
|
|
|
0.17 |
|
|
|
0.25 |
|
|
|
0.36 |
|
Acquisition-related expenses |
|
0.01 |
|
|
|
0.01 |
|
|
|
0.01 |
|
|
|
0.01 |
|
Impairment and abandonment of operating lease right-of-use and other assets related to facilities |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
0.19 |
|
RDS restructuring |
|
0.12 |
|
|
|
— |
|
|
|
0.19 |
|
|
|
— |
|
Executives transition costs |
|
— |
|
|
|
0.02 |
|
|
|
— |
|
|
|
0.02 |
|
Severance-related expenses |
|
— |
|
|
|
0.02 |
|
|
|
— |
|
|
|
0.13 |
|
Amortization of debt issuance costs |
|
0.02 |
|
|
|
0.02 |
|
|
|
0.04 |
|
|
|
0.05 |
|
Tax effect of the adjustments above (a) |
|
(0.06 |
) |
|
|
(0.06 |
) |
|
|
(0.11 |
) |
|
|
(0.16 |
) |
Non-GAAP net income per share - diluted |
$ |
0.51 |
|
|
$ |
0.57 |
|
|
$ |
0.54 |
|
|
$ |
0.96 |
|
|
|
|
|
|
|
|
|
||||||||
Reconciliation of GAAP net income (loss) to non-GAAP EBITDA (b): |
|||||||||||||||
GAAP net income (loss) |
$ |
3,735 |
|
|
$ |
3,451 |
|
|
$ |
(11,941 |
) |
|
$ |
(11,549 |
) |
Share-based compensation expense |
|
10,031 |
|
|
|
14,089 |
|
|
|
18,672 |
|
|
|
28,131 |
|
Interest (income) and expense, net |
|
(6,073 |
) |
|
|
(4,410 |
) |
|
|
(11,788 |
) |
|
|
(7,484 |
) |
Depreciation and amortization expense |
|
20,837 |
|
|
|
22,080 |
|
|
|
42,090 |
|
|
|
44,054 |
|
Acquisition-related expenses |
|
246 |
|
|
|
246 |
|
|
|
492 |
|
|
|
492 |
|
Impairment and abandonment of operating lease right-of-use and other assets related to facilities |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
8,420 |
|
RDS restructuring |
|
5,639 |
|
|
|
— |
|
|
|
8,911 |
|
|
|
— |
|
Executives transition costs |
|
— |
|
|
|
841 |
|
|
|
— |
|
|
|
841 |
|
Severance-related expenses |
|
— |
|
|
|
721 |
|
|
|
— |
|
|
|
6,035 |
|
Amortization of debt issuance costs |
|
972 |
|
|
|
1,046 |
|
|
|
1,943 |
|
|
|
2,091 |
|
Benefit from income taxes |
|
4,462 |
|
|
|
8,758 |
|
|
|
2,307 |
|
|
|
2,576 |
|
Non-GAAP EBITDA |
$ |
39,849 |
|
|
$ |
46,822 |
|
|
$ |
50,686 |
|
|
$ |
73,607 |
|
Non-GAAP EBITDA margin (non-GAAP EBITDA as a % of total revenues) |
|
|
|
|
|
|
|
||||||||
_________________________________________________ |
||
(a) |
|
Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of |
(b) |
|
Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. |
Omnicell, Inc. |
|||||||||||||||
Reconciliation of GAAP to Non-GAAP |
|||||||||||||||
(Unaudited, in thousands) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
|
|
|
|
|
|
|
|
||||||||
Reconciliation of GAAP net cash provided by operating activities to non-GAAP free cash flow: |
|||||||||||||||
GAAP net cash provided by operating activities |
$ |
58,700 |
|
|
$ |
72,903 |
|
|
$ |
108,653 |
|
|
$ |
85,673 |
|
External-use software development costs |
|
(3,998 |
) |
|
|
(3,186 |
) |
|
|
(7,381 |
) |
|
|
(6,685 |
) |
Purchases of property and equipment |
|
(9,551 |
) |
|
|
(11,631 |
) |
|
|
(18,508 |
) |
|
|
(21,772 |
) |
Non-GAAP free cash flow |
$ |
45,151 |
|
|
$ |
58,086 |
|
|
$ |
82,764 |
|
|
$ |
57,216 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801890749/en/
Kathleen Nemeth
Senior Vice President, Investor Relations
650-435-3318
Kathleen.Nemeth@Omnicell.com
Source: Omnicell, Inc.
FAQ
What were Omnicell's (OMCL) Q2 2024 revenue and earnings results?
How has Omnicell (OMCL) updated its 2024 financial guidance?
What is the status of Omnicell's (OMCL) XT Amplify program?
How much cash and debt does Omnicell (OMCL) have as of Q2 2024?
